相关实验视频
Updated: Aug 16, 2026

12:59
Barnes Maze Testing Strategies with Small and Large Rodent Models
Published on: February 26, 2014
43.3K
2'-糖乳糖在AD小鼠中改善认知障碍和神经炎症
Yumeng Ma1, Ming Zhang2, Yutong Jin1
1Key Laboratory of Precision Nutrition and Food Quality, Department of Nutrition and Health, China Agricultural University, Beijing 100193, China.
Journal of agricultural and food chemistry
|September 30, 2025
概括
补充2′-Fucosyllactose (2′-FL) 改善了阿尔茨海默氏症患者的认知缺陷.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 免疫学 免疫学 免疫学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病.
- 在AD中,突触可塑性和神经元完整性受到损害.
- 神经炎症和氧化应激是AD的关键病理特征.
研究的目的:
- 为了评估2′-福科西拉克托斯 (2′-FL) 对阿尔茨海默病的治疗效果.
- 在AD小鼠模型中研究2′-FL对认知功能,神经元损伤,神经炎症和氧化应激的影响.
主要方法:
- 将2′-FL给5×FAD小鼠使用了11周.
- 使用行为测试评估认知缺陷.
- 评估神经元完整性,突触可塑性标记物 (胆固醇和谷氨酸神经元),微质激活和炎症标记物 (IL-6,IL-1β).
- 通过Keap1-Nrf2途径和Nqo1表达的氧化应激的分析.
- 在便和血清中测量特定的脂代谢物 (PC和DG).
主要成果:
- 2′-FL补充剂显著改善了5 × FAD小鼠的认知缺陷.
- 2′-FL治疗改善了神经元损伤,恢复了突触可塑性,并减少了微质激活.
- 观察到IL-6和IL-1βmRNA表达的下调和氧化应激的缓解.
- 2′-FL降低了与AD相关的特定脂代谢物 (PC和DG) 的增加,这与炎症和突触可塑性相关.
结论:
- 2′-Fucosyllactose在阿尔茨海默病中显示出显著的治疗潜力.
- 2′-FL通过调节神经炎症,氧化应激和突触可塑性来产生神经保护作用.
- 这项研究为在治疗神经退行性疾病中使用2′-FL提供了理论基础.
关键词:
2′-fucosyllactose是什么意思 2′-fucosyllactose是什么意思 2′-fucosyllactose是什么意思阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.胆固醇神经元是一种神经元.谷氨酸作用的神经元.神经炎症是一种神经炎症.氧化应激是一种氧化应激.更多相关视频
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
44.1K
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.3K
相关概念视频
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...